The AMAS
Cancer test is an innovative test that is based on levels of a
specific antibody, shown to be elevated in a wide range of cancer
types. This makes it different from most cancer tests which
generally measure levels of an antigen associated with a particular
cancer type.
Most people are unaware that there is a reliable,
scientifically proven laboratory blood test for detecting over 99%
of all cancers.
AMAS stands for
"anti-malignin antibody in serum." The test is extremely sensitive;
blood levels of this antibody rise early in the course of the vast
majority of cancers of all types, regardless of location in the
body. The test is especially useful when cancer is suspected but has
not been confirmed by a biopsy.
One study involving
the test was published in the journal Cancer Detection and Prevention in
1994. In 125 patients and controls, 118 were subsequently diagnosed
by the time the article was published. In 21 individuals who were
subsequently proven to have cancer, the AMAS test was elevated. The
test was normal in 94, none of whom were shown to have cancer. In
three other subjects who did not have cancer, the test was elevated
when first done but a second test was normal. The other seven
subjects had positive AMAS tests but remained undiagnosed at the
time of the article, but all showed symptoms of cancer that likely
indicated its presence.
The study was
consistent with other published tests that indicate that the AMAS
test is over 95% reliable on the first test, and over 99% reliable
when a repeat test is performed. The test is a standardized,
validated assay, developed over 15 years ago by Peter Bogovich,
M.D., Ph.D. Dr. Bogovich has conducted scores of studies and
published widely on the test.
Another study
published in the Journal of Cellular
Biochemistry in 1994 stated that levels typically rise with
age and are higher in individuals at high risk for cancer because of
family history, but stay within normal levels even when benign
growths occur. "We demonstrated that the concentration is most
markedly increased within weeks of the occurrence of malignant
transformation to clinical breast cancer," these researchers wrote.
This study involved breast cancer, but the test is valid for all
cancer types. Other researchers have written that the test is an
excellent screening method.
The AMAS test also is
useful in monitoring the treatment of malignancies. Levels typically
return to normal within two to three months of successful treatment.
Other biological markers in the blood are much less specific and are
usually not elevated early in the course of disease or recurrence.
Thus the AMAS test is an excellent way to screen for and detect
cancer or recurrences, and to track treatment progress during
treatment. Conventional cancer treatment authorities are committed
to a host of expensive but highly profitable diagnostic (and
treatment) techniques (mammograms, MRIs, gastrointestinal series,
etc.). Were it not for the intransigence of established authorities,
the AMAS test undoubtedly would be much more widely used.
The AMAS test should
be ordered and interpreted by a physician experienced with the test.
False negatives and positives do occur. The AMAS test is available
only to Dr. Handwerger's patients.
| 
